国药现代：全资子公司国药集团容生制药有限公司获得布美他尼注射液《药品注册证书》

Core Viewpoint - The announcement indicates that China National Pharmaceutical Group Modern has received approval for the registration of Bumetanide injection from the National Medical Products Administration, which expands its product offerings in the pharmaceutical market [1] Group 1: Product Approval - The approval is for Bumetanide injection, which is primarily used for treating edema-related diseases, hypertension, prevention of acute renal failure, hyperkalemia, hypercalcemia, dilutional hyponatremia, syndrome of inappropriate antidiuretic hormone secretion, and acute drug poisoning [1]